Clinical Trials Directory

Trials / Completed

CompletedNCT00702546

Follow-up Protocol on the Outcome of Frozen-thawed Embryo Transfer Cycles From Clinical Trial P05690 (P05711)

Follow-up Protocol to Collect the Outcome of Frozen-thawed Embryo Transfer Cycles After Cryopreservation of Embryos in Clinical Trial 107012

Status
Completed
Phase
Study type
Observational
Enrollment
102 (actual)
Sponsor
Organon and Co · Industry
Sex
Female
Age
18 Years – 36 Years
Healthy volunteers
Not accepted

Summary

Clinical trial objective is to collect the outcome of Frozen-Thawed Embryo Transfer (FTET) cycles performed after the embryos are cryopreserved in the base study P05690 in order to estimate the cumulative pregnancy rate for each treatment group.

Detailed description

This is a follow-up protocol to collect the outcome of FTET cycles, performed after the embryos are cryopreserved in base study P05690 (NCT00702845), to enable estimation of the cumulative pregnancy rate for each treatment group.

Conditions

Interventions

TypeNameDescription
DRUGcorifollitropin alfaSingle injection of 100 μg corifollitropin alfa administered under protocol P05690
BIOLOGICALrecFSH (follitropin alfa)Daily recFSH administered under protocol P05690
DRUGgonadatropin releasing hormone (GnRH) antagonist ganirelixGnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
DRUGhuman chorion gonadatropin (hCG)hCG 5,000 IU or 10,000 IU administered SC under protocol P05690
BIOLOGICALprogesteroneUnder protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
DRUGplacebo-recFSH (follitropin alfa)Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
DRUGplacebo-corifollitropin alfaSingle SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
BIOLOGICALopen-label recFSHOpen-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P0590

Timeline

Start date
2006-12-01
Primary completion
2008-12-01
Completion
2008-12-01
First posted
2008-06-20
Last updated
2022-02-03
Results posted
2015-05-05

Source: ClinicalTrials.gov record NCT00702546. Inclusion in this directory is not an endorsement.